Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab + Thalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT01632150Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2012
- Primary completion
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elotuzumab in multiple myeloma (MM), sponsored by Bristol Myers Squibb. Primary endpoints: Percentage of Participants Who Received Treatment Including Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events and Percentage of All Participants Who Received Treatment Without Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events. Started May 2012; status: completed.
02
Drugs
elotuzumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01632150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632150.